Cancer researcher becomes The US Oncology Network’s chief scientific officer

Robert Coleman
Robert L. Coleman

The US Oncology Network named Robert L. Coleman, MD, FACOG, FACS, its new chief scientific officer.

Coleman — the senior-most clinician scientist on The US Oncology Network leadership team — will lead US Oncology Research, which draws from a network of more than 1,000 investigators and clinical staff who specialize in oncology clinical trials.

Coleman will work to develop the infrastructure and support necessary to make participating in research more accessible to all physicians in the network. He also will identify opportunities and develop strategies to work with manufacturers and biopharma companies, as well as evaluate emerging technologies, digital platforms and artificial intelligence strategies.

“The US Oncology Network is a worldwide leader in cancer research, and the organization is strongly committed to advancing the fight against cancer while making novel therapies available to patients in local communities,” Coleman said in a press release. “I am excited to have the opportunity to help enhance and expand the research program by collaborating with the leadership team and the many dedicated researchers, physicians and staff who have made the program such a great success already.”

Coleman most recently served as executive director of The University of Texas MD Anderson Cancer Center’s network research program, as well as Ann Rife Cox chair in gynecology in the department of gynecologic oncology and reproductive medicine at MD Anderson.

“We are honored to have someone of Dr. Coleman’s stature join our leadership team,” Michael V. Seiden, MD, PhD, president of The US Oncology Network, said in a press release. “He is an internationally recognized leader in ovarian cancer research and has been instrumental in developing many of the promising treatments that are now available for ovarian cancer management. His strong background in clinical research and his deep expertise in creating and managing research programs in various care delivery settings make him an excellent fit for our organization as we continue to grow and enhance our research program.”

The US Oncology Network — supported by McKesson Corporation — is one of the nation’s largest networks of integrated, community-based oncology practices.

Robert Coleman
Robert L. Coleman

The US Oncology Network named Robert L. Coleman, MD, FACOG, FACS, its new chief scientific officer.

Coleman — the senior-most clinician scientist on The US Oncology Network leadership team — will lead US Oncology Research, which draws from a network of more than 1,000 investigators and clinical staff who specialize in oncology clinical trials.

Coleman will work to develop the infrastructure and support necessary to make participating in research more accessible to all physicians in the network. He also will identify opportunities and develop strategies to work with manufacturers and biopharma companies, as well as evaluate emerging technologies, digital platforms and artificial intelligence strategies.

“The US Oncology Network is a worldwide leader in cancer research, and the organization is strongly committed to advancing the fight against cancer while making novel therapies available to patients in local communities,” Coleman said in a press release. “I am excited to have the opportunity to help enhance and expand the research program by collaborating with the leadership team and the many dedicated researchers, physicians and staff who have made the program such a great success already.”

Coleman most recently served as executive director of The University of Texas MD Anderson Cancer Center’s network research program, as well as Ann Rife Cox chair in gynecology in the department of gynecologic oncology and reproductive medicine at MD Anderson.

“We are honored to have someone of Dr. Coleman’s stature join our leadership team,” Michael V. Seiden, MD, PhD, president of The US Oncology Network, said in a press release. “He is an internationally recognized leader in ovarian cancer research and has been instrumental in developing many of the promising treatments that are now available for ovarian cancer management. His strong background in clinical research and his deep expertise in creating and managing research programs in various care delivery settings make him an excellent fit for our organization as we continue to grow and enhance our research program.”

The US Oncology Network — supported by McKesson Corporation — is one of the nation’s largest networks of integrated, community-based oncology practices.